Ibrutinib, a first-in-class orally bioavailable, small-molecule inhibitor of BTK, was approved in the United States for the treatment of patients with relapsed or refractory MCL and CLL, as well as patients with CLL who have deletion 17p. The gene discussed is BTK; the disease is mantle cell lymphoma.